广告
加载中

京东健康Q1营收增长17% :广告收入和医药供应链优势贡献主要增量

亿邦动力 2026-05-13 11:14
亿邦动力 2026/05/13 11:14

邦小白快读

EN
全文速览

本文核心是京东健康2026年第一季度的财报业绩和业务增长情况,核心干货整理如下:

1.业绩数据:京东健康Q1实现营收194.68亿元,同比增长17%,多项盈利指标增速亮眼,经营盈利同比增70.4%,期内盈利同比增78.2%;虽然受2025年高基数影响,增速较去年同期有所放缓,但营收规模依旧创下一季度历史新高,2025年全年四个季度增速都维持20%以上,整体保持稳定高增长态势。

2.业务亮点:增长核心来自医药供应链优势和医疗AI落地,一季度首发30余款创新药,保持全网新药首发第一的地位,自研医疗大模型登顶行业权威评测双榜第一,多款AI医疗产品已经多端口落地,AI医生用户量已经超过2025年全年总和,同时还新拓展了AI+医疗器械、宠物健康等业务。

本文披露了大健康领域的最新增长趋势和合作机会,干货内容整理如下:

1.行业增长逻辑:当前头部互联网健康平台的核心增长动力为供应链优势叠加AI技术落地,品牌商可以借力头部平台的供应链优势,推出创新产品,京东健康作为头部平台,开放新药首发资源,目前已经有诺华、欧加隆等多家知名药企达成战略合作,借助平台触达更多用户。

2.细分市场机会:AI+医疗器械的适老场景已经成为平台重点布局方向,平台计划推动百万台医疗器械接入智能系统,相关品牌可以对接合作;宠物健康赛道平台正在打造品质生态联盟,推出专属服务,品牌可以参与生态建设获得流量扶持;另外平台高毛利广告业务增长超20%,品牌投放的效果空间更大,可优先布局。

本文给大健康领域卖家披露了平台发展现状和增长机会,干货整理如下:

1.平台经营基础:京东健康2026Q1实现营收194.68亿元,同比增长17%,多项盈利指标大幅增长,平台自身盈利状况良好,当前还将增量利润投入到O2O业务扩张和AI研发中,中长期增长稳定,给卖家提供了可靠的经营基础。

2.增长机会提示:新药首发是平台核心战略方向,入驻卖家推出创新药可获得平台流量倾斜;AI+适老医疗器械是平台重点拓展品类,平台计划接入百万台相关设备,器械类卖家可优先对接合作资源;宠物健康领域平台正在搭建品质生态联盟,推出了“宠物金选”“无效包退”等服务,宠物类卖家可参与生态合作获得扶持;平台广告业务增长快,站内投放需求旺盛,卖家可布局广告投放拉动增长。

本文给大健康领域生产工厂带来了产品方向、数字化转型的启示和商业机会,干货整理如下:

1.产品研发方向:当前创新药、智能化适老医疗器械、宠物健康相关产品都是头部平台重点发展的方向,工厂可针对性调整生产和研发计划,布局创新品类,对接平台的首发资源打开销路。

2.数字化转型启示:京东健康正在推进JoyInside智能互联系统在适老医疗器械场景的落地,计划推动百万台设备接入,工厂可以借力头部平台的AI技术能力,推进自身产品的智能化升级,适配新场景的用户需求,提升产品竞争力。

3.商业合作机会:头部平台正在和药企、医疗器械品牌深化供应链合作,开放自身的渠道和技术资源,符合方向的生产工厂可对接平台合作,获得稳定的销售渠道和技术支持。

本文披露了大健康互联网行业的发展趋势和客户需求,给服务商带来干货参考如下:

1.行业发展趋势:当前头部互联网健康平台已经进入供应链+技术双驱动的增长阶段,医疗AI全场景落地是核心发展方向,京东健康自研医疗大模型已经跻身全球领先行列,AI已经融入医、检、诊、药全服务闭环,成为行业发展的核心风向。

2.客户痛点与合作机会:头部平台当前正在扩张O2O业务、加大AI技术研发力度,同时推进百万台医疗器械智能化接入,拓展宠物健康生态,需要大量AI技术服务商、生态运营服务商参与合作;另外平台广告业务增长超过20%,品牌投放需求旺盛,也需要营销服务商提供配套的投放运营服务,相关服务商可对接头部平台的合作需求,拓展自身客户群体。

本文披露了京东健康的最新业务布局,给健康领域平台商带来很多参考干货,整理如下:

1.核心能力建设参考:平台要把医药供应链能力作为核心支撑,把新药首发打造成核心差异化竞争力,同时要发力自研医疗AI核心技术,推进AI全场景落地,打通多流量端口,把AI融入全服务链路,提升用户体验和经营效率。

2.新业务拓展方向:平台可参考布局AI+医疗器械适老场景,以及宠物健康新赛道,通过和头部品牌、机构搭建生态联盟的方式,快速拓展业务边界,打开新增长空间。

3.经营策略参考:在高基数导致增速放缓的阶段,平台可以通过提升经营效率、发力高毛利广告业务拉动短期盈利,同时将增量利润投入到中长期技术研发和业务扩张中,平衡短期盈利和长期增长,为后续发展储备动力。

本文披露了互联网医疗行业的最新发展动向,对产业研究有较高参考价值,干货整理如下:

1.产业发展新动向:当前互联网医疗行业已经走出早期烧钱扩张的阶段,进入盈利增长的成熟阶段,头部企业京东健康已经实现连续多个季度20%以上的高增长,2026Q1受高基数影响增速放缓,但盈利依旧大幅增长,整体行业已经进入盈利与长期投入并行的发展阶段。

2.商业模式新特征:头部平台已经形成了成熟的可持续商业模式,即以医药供应链为核心底座做大营收规模,以医疗AI全场景落地为新增长引擎提升服务效率,通过高毛利广告业务提升盈利水平,再将增量利润投入到研发和新业务扩张中,形成正向增长循环。

3.新增长点:AI+医疗器械、宠物健康已经成为互联网医疗新的细分增长点,产业模式逐渐清晰,值得深入研究。

返回默认

声明:快读内容全程由AI生成,请注意甄别信息。如您发现问题,请发送邮件至 run@ebrun.com 。

我是 品牌商 卖家 工厂 服务商 平台商 研究者 帮我再读一遍。

Quick Summary

This article focuses on JD Health's Q1 2026 financial performance and business growth, with key takeaways as follows:

1. Performance data: JD Health posted 19.468 billion yuan in revenue in Q1, up 17% year-over-year. Multiple profitability metrics posted strong growth: operating profit climbed 70.4% year-over-year, and net profit for the period rose 78.2% year-over-year. While growth moderated from the year-ago period due to a high base of comparison in 2025, revenue still hit a new all-time high for any first quarter. JD Health maintained growth above 20% across all four quarters of 2025, putting it on a solid trajectory of stable high growth overall.

2. Business highlights: Growth is primarily driven by the company's advantages in pharmaceutical supply chain and the commercial rollout of medical AI. It launched more than 30 innovative new drugs exclusively in Q1, retaining its leading position as the top platform for first drug launches across the Chinese internet. Its self-developed large medical language model claimed the top spot on two authoritative industry benchmark rankings, and multiple AI-powered healthcare products are now available across multiple user endpoints. The cumulative user base of its AI doctor has already surpassed the full-year total for 2025. The company has also expanded into new segments including AI-integrated medical devices and pet healthcare.

This article outlines the latest growth trends and partnership opportunities in China's big health industry, with key insights as follows:

1. Industry growth drivers: Leading online health platforms are currently growing on the combined strength of supply chain advantages and AI adoption. Brands can leverage leading platforms' supply chain capabilities to launch innovative products. As a top industry player, JD Health opens up exclusive resources for first drug launches, and has already established strategic partnerships with major global pharmaceutical companies including Novartis and Organon, helping brands reach far more end users.

2. Opportunities in niche segments: AI-enabled medical devices for senior care is a core strategic focus for the platform, which plans to connect 1 million medical devices to its smart system. Relevant brands can partner on this initiative. The platform is also building a quality ecosystem alliance for the pet health track, and offers exclusive support for participating brands, which can gain traffic benefits by joining the ecosystem. In addition, JD Health's high-margin advertising business grew more than 20%, offering brands stronger return on spending, making this a priority for marketing investment.

This article shares platform updates and growth opportunities for sellers in the big health sector, with key takeaways as follows:

1. Stable platform foundation: JD Health generated 19.468 billion yuan in Q1 2026 revenue, up 17% year-over-year, with multiple profitability metrics posting strong double-digit growth. The platform is solidly profitable, and is reinvesting incremental profits into O2O business expansion and AI R&D, ensuring stable long-term growth and a reliable operating environment for sellers.

2. Key growth opportunities: First exclusive drug launches are a core strategic priority for the platform, and participating sellers that launch innovative drugs will receive preferential traffic support. AI-enabled senior-focused medical devices are another key expansion area, with the platform planning to connect 1 million such devices, making this a priority partnership opportunity for medical device sellers. In the pet health space, the platform is building a quality ecosystem alliance with tailored services including "JD Pet Premium Selection" and "Money-back Guarantee for Ineffective Products", so pet product sellers can gain support by joining the ecosystem. The platform's advertising business is growing rapidly with strong demand for in-platform marketing, so sellers can invest in advertising to drive sales growth.

This article offers insights on product direction, digital transformation and business opportunities for big health manufacturers, summarized as follows:

1. Product R&D guidance: Innovative drugs, smart senior-focused medical devices, and pet health products are all key growth areas for leading industry platforms. Manufacturers can adjust their R&D and production plans accordingly, focus on these innovative categories, and leverage the platforms' first launch resources to open up new sales channels.

2. Digital transformation insights: JD Health is rolling out its JoyInside smart connectivity system for the senior medical device segment, with a target of connecting 1 million devices. Manufacturers can leverage the leading platform's AI capabilities to upgrade their own products with smart features, adapt to user needs in new scenarios, and improve product competitiveness.

3. Business partnership opportunities: Leading platforms are deepening supply chain collaboration with pharmaceutical and medical device brands, and are opening up their channel and technology resources. Eligible manufacturers that align with the strategic direction can partner with the platform to gain access to stable sales channels and technical support.

This article outlines industry trends and client demand for big health internet services, with key insights for service providers as follows:

1. Industry development trend: Leading online health platforms have entered a phase of dual-driven growth powered by supply chain and technology, with full-scenario deployment of medical AI as the core development direction. JD Health's self-developed large medical language model is already among the world's most advanced, and AI has been integrated into the full closed-loop service covering medical consultation, testing, diagnosis and pharmaceuticals, becoming the core industry trend.

2. Client pain points and partnership opportunities: Leading platforms are currently expanding their O2O businesses, ramping up AI R&D, connecting 1 million smart medical devices, and building out the pet health ecosystem, creating strong demand for partnerships with AI technology service providers and ecosystem operation service providers. In addition, the platform's advertising business grew more than 20% with surging brand marketing demand, creating need for marketing service providers to support campaign operation and management. Relevant service providers can align with leading platforms' partnership needs to expand their client base.

This article shares JD Health's latest business layout, offering key insights for other health industry platforms, summarized as follows:

1. Core capability building reference: Platforms should build pharmaceutical supply chain capacity as their core foundation, position exclusive first drug launches as a key differentiator, invest in in-house development of core medical AI technology, advance full-scenario AI deployment across multiple traffic channels, integrate AI into the entire service chain, and improve both user experience and operational efficiency.

2. New business expansion direction: Platforms can consider entering AI-enabled medical devices for senior care and pet healthcare, two emerging tracks. They can rapidly expand business boundaries and unlock new growth by building ecosystem alliances with leading brands and industry institutions.

3. Operating strategy guidance: When growth slows due to a high base of comparison, platforms can boost near-term profitability by improving operational efficiency and scaling high-margin advertising businesses, while reinvesting incremental profits into long-term R&D and business expansion. This balances near-term profitability and long-term growth to build momentum for future development.

This article shares the latest industry developments in internet healthcare, offering high reference value for industry research, with key insights as follows:

1. New industry development trends: China's internet healthcare industry has moved past the early stage of loss-making expansion and entered a mature phase of profitable growth. Leading player JD Health has maintained over 20% year-over-year growth for multiple consecutive quarters. While its Q1 2026 growth moderated due to a high comparison base, profit still grew sharply. Overall, the industry has entered a development phase of balancing profitable operations and long-term investment.

2. New characteristics of business models: Leading platforms have developed mature, sustainable business models: they build revenue scale around a core pharmaceutical supply chain base, use full-scenario medical AI deployment as a new growth engine to improve service efficiency, lift profitability through high-margin advertising business, and reinvest incremental profits into R&D and new business expansion, forming a positive growth cycle.

3. Emerging growth areas: AI-integrated medical devices and pet health have emerged as new niche growth drivers in internet healthcare, with increasingly clear industry models, making them worthy of in-depth research.

Disclaimer: The "Quick Summary" content is entirely generated by AI. Please exercise discretion when interpreting the information. For issues or corrections, please email run@ebrun.com .

I am a Brand Seller Factory Service Provider Marketplace Seller Researcher Read it again.

【亿邦原创】5月12日,京东健康(06618/86618)发布公告,2026年第一季度,公司收入为194.68亿元,同比增长17%;经营盈利为18.25亿元,同比增长70.4%;期间盈利为16.65亿元,同比增长78.2%;运营利润为18.25亿,较上年同期的10.71亿增长70.4%;经调整运营利润为19.36亿,较上年同期的13亿增长48%;期内利润为16.65亿,较上年同期的9.34亿增长78.2%;经调整净利为18.74亿,较上年同期的17.68亿增长6%。

据亿邦动力统计,京东健康2025年Q1至Q4营收分别为166.45亿元、186亿元、171亿元和210.32亿元,同比增速依次为25.5%、23.6%、28.7%和27.4%,全年维持20%以上的高增长;2026年Q1营收达194.67亿元,受高基数影响同比增速放缓至17.0%,但营收规模仍创一季度新高。

从增长驱动因素来看,医药供应链优势是收入增长的核心支撑。一季度,京东健康首发超过30款新药,其中包括诺华旗下全球首个获批治疗慢性自发性荨麻疹的口服靶向药瑞普多®,以及国内首款治疗白癜风的创新药百卢妥®等,与此同时,公司与欧加隆、科赴、华润江中、首儿药业等多家知名药企达成战略合作。

医疗AI的全场景落地是公司业绩增长的又一重要引擎。在产品层面,“AI京医”智能体集群打通了京东APP、京东健康APP及微信生态,推出“药智模型”“药小智”“全球找药平台”等AI用药服务。AI医生“大为”深度融合了“医、检、诊、药”闭环,能够直接匹配在线问诊、到家快检、护士到家及药品履约。值得关注的是,2026年前三个月,使用AI医生“大为”的用户数已超过2025年全年水平。

此外,京东健康在AI+医疗器械领域也进行了布局,与鱼跃医疗、可孚医疗、讯飞医疗等头部品牌签署战略合作,推进JoyInside智能互联系统在适老场景落地,计划推动百万台医疗器械接入。同时,宠物健康业务上线了“宠物金选”与“无效包退”服务,并联合皇家、瑞派宠物医院成立宠物品质生态联盟,进一步拓展了业务边界。

关于不同盈利指标增速存在差异的原因,经营盈利同比增长70.4%,主要受益于广告等高毛利业务的强劲增长(广告收入增长20%以上)以及经营效率的提升。而非国际财务报告准则期内盈利同比仅增长6.0%,增速相对平稳,主要是公司将增量利润投入于O2O业务扩张和AI技术研发,为中长期增长储备资源。

亿邦持续追踪报道该情报,如想了解更多与本文相关信息,请扫码关注作者微信。

文章来源:亿邦动力

广告
微信
朋友圈

这么好看,分享一下?

朋友圈 分享

APP内打开

+1
+1
微信好友 朋友圈 新浪微博 QQ空间
关闭
收藏成功
发送
/140 0